These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 3165079)

  • 1. [Immunohistochemical demonstration of CA 125, CA 19-9 and CEA in normal and pathologically changed adnexa].
    Neunteufel W; Breitenecker G
    Geburtshilfe Frauenheilkd; 1988 May; 48(5):334-7. PubMed ID: 3165079
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tissue expression of CA 125 in benign and malignant lesions of ovary and fallopian tube: a comparison with CA 19-9 and CEA.
    Neunteufel W; Breitenecker G
    Gynecol Oncol; 1989 Mar; 32(3):297-302. PubMed ID: 2646183
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ovarian tumors of low malignant potential (borderline tumors): immune morphology and current status.
    Neunteufel W; Gitsch G; Schieder K; Kölbl H; Breitenecker G
    Anticancer Res; 1989; 9(4):993-7. PubMed ID: 2684001
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CA 125 and carcinoembryonic antigen levels in cyst fluid, ascites and serum of patients with ovarian neoplasms.
    Harłozińska A; Bar JK; Gawlikowski W; Richter R; Cisło M
    Ann Chir Gynaecol; 1991; 80(4):368-75. PubMed ID: 1667567
    [TBL] [Abstract][Full Text] [Related]  

  • 5. S-100 protein in ovarian tumors. A comparative immunohistochemical study of 135 cases.
    Lin M; Hanai J; Wada A; Ozaki M; Nasu K; Okamoto S; Matsumoto K
    Acta Pathol Jpn; 1991 Mar; 41(3):233-9. PubMed ID: 2068948
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum CA 125, carcinoembryonic antigen, and CA 19-9 as tumor markers in borderline ovarian tumors.
    Engelen MJ; de Bruijn HW; Hollema H; ten Hoor KA; Willemse PH; Aalders JG; van der Zee AG
    Gynecol Oncol; 2000 Jul; 78(1):16-20. PubMed ID: 10873403
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Relationship between serum levels and immunohistological tissue levels of CA 125 and CEA in epithelial ovarian cancers: its implications for tumor cell type specificity].
    Oishi T; Maruo T; Iwasaki M; Mochizuki M
    Nihon Sanka Fujinka Gakkai Zasshi; 1986 Sep; 38(9):1595-604. PubMed ID: 3464659
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Is there a correlation between tumor marker panel and tumor size and histopathology in well staged patients with borderline ovarian tumors?
    Ayhan A; Guven S; Guven ES; Kucukali T
    Acta Obstet Gynecol Scand; 2007; 86(4):484-90. PubMed ID: 17486473
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Tumor markers in gynecologic diseases].
    Geyer H; Kleine W
    Geburtshilfe Frauenheilkd; 1987 Mar; 47(3):168-72. PubMed ID: 3472991
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A comparative study of mucin-like carcinoma-associated antigen (MCA), CA 125, CA 19-9 and CEA in patients with ovarian cancer.
    Koelbl H; Schieder K; Neunteufel W; Bieglmayer C
    Neoplasma; 1989; 36(4):473-8. PubMed ID: 2770933
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oviductal glycoprotein, a new differentiation-based indicator present in early ovarian epithelial neoplasia and cortical inclusion cysts.
    Woo MM; Gilks CB; Verhage HG; Longacre TA; Leung PC; Auersperg N
    Gynecol Oncol; 2004 May; 93(2):315-9. PubMed ID: 15099939
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Detection of blood-borne cells in colorectal cancer patients by nested reverse transcription-polymerase chain reaction for carcinoembryonic antigen messenger RNA: longitudinal analyses and demonstration of its potential importance as an adjunct to multiple serum markers.
    Guadagni F; Kantor J; Aloe S; Carone MD; Spila A; D'Alessandro R; Abbolito MR; Cosimelli M; Graziano F; Carboni F; Carlini S; Perri P; Sciarretta F; Greiner JW; Kashmiri SV; Steinberg SM; Roselli M; Schlom J
    Cancer Res; 2001 Mar; 61(6):2523-32. PubMed ID: 11289125
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Analysis of serum CA125, CEA, AFP, LDH levels and LDH isoenzymes in patients with ovarian tumors--correlation between tumor markers and histological types of ovarian tumors].
    Konishi I; Fujii S; Okamura H; Sakahara H; Endo K; Torizuka K; Suzuki A; Mori T
    Nihon Sanka Fujinka Gakkai Zasshi; 1986 Jun; 38(6):827-36. PubMed ID: 2426374
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Telomerase activity as a biological marker in some gynecological tumors: comparison with tissue and serum CA 125.
    Novakovic S; Fras PA; Jezersek-Novakovic B
    In Vivo; 2001; 15(4):327-32. PubMed ID: 11695225
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunohistochemical evaluation of sialosyl-Tn antigens in various ovarian carcinomas.
    Ryuko K; Iwanari O; Kitao M; Moriwaki S
    Gynecol Oncol; 1993 May; 49(2):215-24. PubMed ID: 8504990
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A comparative study of serum alpha-beta A immunoreactive inhibin and tumor-associated antigens CA125 and CEA in ovarian cancer.
    Phocas I; Sarandakou A; Sikiotis K; Rizos D; Kalambokis D; Zourlas PA
    Anticancer Res; 1996; 16(6B):3827-31. PubMed ID: 9042265
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differentiation margins of ovarian tumor pathology: first incidences of epithelial ovarian tumors monitored by marker antibodies.
    van Niekerk CC; Vooijs P; Casparie-van Velsen IJ; Poels LG
    Cancer Detect Prev; 1997; 21(3):247-57. PubMed ID: 9167042
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunohistochemical staining of GLUT1 in benign, borderline, and malignant ovarian epithelia.
    Kalir T; Wang BY; Goldfischer M; Haber RS; Reder I; Demopoulos R; Cohen CJ; Burstein DE
    Cancer; 2002 Feb; 94(4):1078-82. PubMed ID: 11920478
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of monoclonal antibody-defined tumor markers in four carcinomas.
    Wu JT
    Ann Clin Lab Sci; 1989; 19(1):17-26. PubMed ID: 2916833
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunohistochemical characterization of ovarian borderline tumors of intestinal and mullerian types.
    Rutgers JL; Bell DA
    Mod Pathol; 1992 Jul; 5(4):367-71. PubMed ID: 1495942
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.